Quick Answer
ABEONA THERAPEUTICS INC. reported Operating Income Loss of -$89.45 million for the year ending 2025.
- ABEONA THERAPEUTICS INC. showed a decrease of -39.3% in Operating Income Loss from 2024 to 2025.
- This data is from ABEONA THERAPEUTICS INC.'s annual report (Form 10-K), filed with the SEC on March 17, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2011: -$2.15 million | Q2 2011: -$2.25 million | Q3 2011: -$1.78 million | Q1 2012: -$689.0 thousand | Q2 2012: -$1.45 million | Q3 2012: -$956.0 thousand | Q1 2013: -$503.0 thousand | Q2 2013: -$1.92 million | Q3 2013: -$696.0 thousand | Q1 2014: -$1.33 million | Q2 2014: -$703.0 thousand | Q3 2014: -$633.0 thousand | Q1 2015: -$2.00 million | Q2 2015: -$4.13 million | Q3 2015: -$6.16 million | Q1 2016: -$6.16 million | Q2 2016: -$6.72 million | Q3 2016: -$5.17 million | Q1 2017: -$5.28 million | Q2 2017: -$8.44 million | Q3 2017: -$5.36 million | Q4 2017: -$8.75 million | Q1 2018: -$10.68 million | Q2 2018: -$12.56 million | Q3 2018: -$16.92 million | Q4 2018: -$18.01 million | Q1 2019: -$19.05 million | Q2 2019: -$23.98 million | Q3 2019: -$17.65 million | Q4 2019: -$16.41 million | Q1 2020: -$48.21 million | Q2 2020: -$12.48 million | Q3 2020: -$6.25 million | Q1 2021: -$14.60 million | Q2 2021: -$13.72 million | Q3 2021: -$14.87 million | Q1 2022: -$20.59 million | Q2 2022: -$8.01 million | Q3 2022: -$9.38 million | Q1 2023: -$12.04 million | Q2 2023: -$10.55 million | Q3 2023: -$11.33 million | Q1 2024: -$14.33 million | Q2 2024: -$17.86 million | Q3 2024: -$15.35 million | Q1 2025: -$19.73 million | Q2 2025: -$22.79 million | Q3 2025: -$24.02 million.
- Over the full 16 years of available data (2010 to 2025), ABEONA THERAPEUTICS INC.'s Operating Income Loss has declined by 1,053.1%.
- Historical annual values: Fiscal year 2025: -$89.45 million | Fiscal year 2024: -$64.21 million | Fiscal year 2023: -$47.14 million | Fiscal year 2022: -$50.92 million | Fiscal year 2021: -$89.84 million | Fiscal year 2020: -$81.42 million | Fiscal year 2019: -$77.09 million | Fiscal year 2018: -$58.17 million | Fiscal year 2017: -$27.84 million | Fiscal year 2016: -$23.88 million | Fiscal year 2015: -$18.55 million | Fiscal year 2014: -$3.13 million | Fiscal year 2013: -$3.80 million | Fiscal year 2012: -$4.32 million | Fiscal year 2011: -$7.88 million | Fiscal year 2010: -$7.76 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: